Rituximab in treatment of post-transplant lymphoproliferative disease after allogeneic stem cell transplantation

Lidia Gil; Jan Styczyński

doi:10.5114/wo.2011.23005

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2011
vol. 15

Send email

Copy url:

abstract:

Review paper

Rituximab in treatment of post-transplant lymphoproliferative disease after allogeneic stem cell transplantation

Lidia Gil

,

Jan Styczyński

Współcz Onkol 2011; 15 (3): 155–158

DOI: https://doi.org/10.5114/wo.2011.23005

Online publish date: 2011/07/04

View full text Get citation

PlumX metrics:

Post-transplant lymphoproliferative disease (PTLD) after haematopoietic stem cell transplantation is a life-threatening complication and the number of patients at risk is increasing over time. In the majority of patients Epstein-Barr virus-related PTLD (EBV-PTLD) is diagnosed with a histological picture of B-cell lymphoma. In 2009 recommendations for diagnosis, monitoring and treatment of patients with EBV-PTLD were published. Definitions of preemptive treatment and therapy of probable or proven PTLD were introduced. Results of preemptive treatment and therapy of documented PTLD are discussed in this paper, with the emphasis on monoclonal antibody anti-CD20 rituximab effectiveness and indications for its applications. A comprehensive review of reported cases of PTLD and summary of results indicate that rituximab in monotherapy or in combination treatment is successful in 63% of confirmed PTLD cases and in 89% when used preemptively. Still, an analysis of factors determining the response to therapy is lacking.

keywords:

Rituximab in treatment of post-transplant lymphoproliferative disease after allogeneic stem cell transplantation

Lidia Gil , Jan Styczyński

Epstein-Barr virus, post-transplant lymphoproliferative disease, haematopoietic stem cell transplantation

Lidia Gil

,

Jan Styczyński